
  
    
      
        
        In_IN 1997_CD ,_, United_NNP States_NNPS President_NNP Bill_NNP Clinton_NNP announced_VBD the_DT challenge_NN to_TO develop_VB an_DT AIDS_NNP
        vaccine_NN by_IN 2007_CD ._. Since_IN 1997_CD ,_, the_DT AIDS_NNP Vaccine_NNP Advocacy_NNP Coalition_NNP (_( AVAC_NNP )_) has_VBZ published_VBN
        annual_JJ reports_NNS on_IN the_DT global_JJ status_NN of_IN the_DT effort_NN to_TO meet_VB Clinton_NNP 's_POS deadline_NN ._. Last_JJ year_NN 's_POS
        report_NN ,_, entitled_VBD “ AIDS_NNP Vaccine_NNP Trials—_NNP Getting_VBG the_DT Global_NNP House_NNP in_IN Order_NNP ,_,” officially_RB ends_VBZ
        the_DT countdown_NN ._. Saying_VBG that_IN “ we_PRP are_VBP on_IN a_DT long_JJ term_NN mission_NN ,_,” AVAC_NNP concludes_VBZ that_IN there_EX will_MD
        not_RB be_VB a_DT safe_JJ and_CC efficient_JJ vaccine_NN in_IN 2007_CD ,_, and_CC that_IN we_PRP need_VBP to_TO “ focus_VB on_IN the_DT long_JJ haul_NN
        and_CC set_VBD an_DT agenda_NN for_IN sustained_VBN and_CC sustainable_JJ action_NN that_WDT stretches_VBZ well_RB beyond_IN 2007_CD ._.” It_PRP
        is_VBZ not_RB that_IN there_EX are_VBP no_DT vaccine_NN candidates_NNS in_IN clinical_JJ trials_NNS ,_, but_CC there_EX is_VBZ little_JJ hope_NN
        that_IN any_DT of_IN the_DT current_JJ candidates_NNS will_MD turn_VB out_RP to_TO be_VB a_DT cheap_JJ and_CC safe_JJ vaccine_NN that_WDT
        affords_NNS long-term_JJ protection_NN ._.
        Among_IN notable_JJ developments_NNS over_IN the_DT past_JJ 12_CD months_NNS ,_, the_DT AVAC_NNP report_NN highlights_VBZ the_DT
        Global_NNP HIV_NNP /_NN AIDS_NNP Vaccine_NNP Enterprise_NNP as_IN an_DT effort_NN to_TO improve_VB coordination_NN within_IN the_DT AIDS_NNP
        vaccine_NN field_NN ._. The_DT Enterprise_NNP was_VBD announced_VBN in_IN June_NNP 2003_CD and_CC now_RB shares_VBZ its_PRP$ scientific_JJ
        strategic_JJ plan_NN with_IN everyone_NN affected_VBN by_IN the_DT AIDS_NNP pandemic—that_NN is_VBZ ,_, all_DT of_IN us—by_NN publishing_NN
        it_PRP in_IN 
        PLoS_NNP Medicine_NNP (_( DOI_NNP :_: 10_CD ._. 1371_CD /_NN journal_NN ._. pmed_JJ ._. 0020025_CD )_) ._.
        In_IN its_PRP$ plan_NN the_DT Enterprise_NNP presents_VBZ itself_PRP as_IN a_DT global_JJ endeavor_NN and_CC emphasizes_VBZ the_DT need_NN
        for_IN integration_NN and_CC capacity_NN building_NN around_IN the_DT world_NN ._. It_PRP is_VBZ not_RB “ a_DT discrete_JJ organization_NN
        with_IN a_DT pool_NN of_IN money_NN” but_CC a_DT “ coordinating_VBG group_NN of_IN individual_JJ funding_NN agencies_NNS that_WDT will_MD
        support_VB specific_JJ areas_NNS of_IN research_NN using_VBG their_PRP$ own_JJ mechanisms_NNS ,_, according_VBG to_TO their_PRP$ own_JJ
        practices_NNS and_CC policies_NNS ,_, and_CC following_VBG the_DT Enterprise_NNP 's_POS principles_NNS ._.” These_DT principles_NNS
        include_VBP collaboration_NN ,_, standardization_NN ,_, and_CC coordination_NN among_IN international_JJ researchers_NNS
        and_CC agencies_NNS ._. The_DT plan_NN focuses_VBZ on_IN specific_JJ scientific_JJ roadblocks_NNS that_WDT need_VBP to_TO be_VB overcome_VBN ,_,
        but_CC also_RB looks_VBZ ahead_RB and_CC mentions_VBZ the_DT need_NN to_TO build_VB capacity_NN for_IN product_NN manufacturing_NN and_CC
        clinical_JJ trials_NNS ,_, and_CC to_TO address_VB regulatory_JJ issues_NNS ._.
        These_DT are_VBP noble_JJ goals_NNS ,_, and_CC the_DT fact_NN that_IN they_PRP are_VBP stipulated_VBD jointly_RB by_IN many_JJ of_IN the_DT
        leaders_NNS in_IN the_DT field_NN will_MD generate_VB excitement_NN and_CC expectations_NNS ,_, even_RB though_IN much_JJ of_IN what_WP is_VBZ
        said_VBN has_VBZ been_VBN said_VBN before_RB ._. The_DT plan_NN stresses_VBZ collaboration_NN and_CC coordination_NN ;_: there_EX are_VBP
        clear_JJ benefits_NNS from_IN a_DT concerted_JJ effort_NN ._. But_CC might_MD a_DT level_NN of_IN competition_NN ,_, rather_RB than_IN
        collaboration_NN ,_, be_VB healthy_JJ ,_, and_CC ,_, if_IN so_RB ,_, what_WP level_NN of_IN competition_NN would_MD work_VB best_JJS ?_. The_DT
        Enterprise_NNP members_NNS seem_VBP to_TO have_VB wrestled_JJ with_IN that_DT question_NN ._. The_DT plan_NN mentions_VBZ an_DT
        “ appropriate_JJ balance_NN between_IN productive_JJ competition_NN and_CC effective_JJ collaboration_NN ,_,” and_CC
        suggests_VBZ that_IN certain_JJ incentives_NNS could_MD be_VB provided_VBN by_IN “ the_DT funders_NNS with_IN greatest_JJS
        flexibility_NN ._.” As_RB long_RB as_IN it_PRP remains_VBZ unclear_JJ where_WRB scientific_JJ breakthroughs_NNS will_MD come_VB from_IN ,_,
        diversity_NN and_CC flexibility_NN should_MD be_VB encouraged_VBN and_CC not_RB stifled_JJ ._. David_NNP Ho_NNP ,_, in_IN his_PRP$
        Perspective_NNP on_IN the_DT plan_NN (_( DOI_NNP :_: 10_CD ._. 1371_CD /_NN journal_NN ._. pmed_JJ ._. 0020036_CD )_) ,_, mentions_VBZ the_DT danger_NN of_IN “ group_NN
        think_VBP ,_,” and_CC the_DT Enterprise_NNP must_MD not_RB fall_VB into_IN that_DT trap_NN ._.
        Notably_RB absent_JJ from_IN this_DT initial_JJ plan_NN is_VBZ any_DT mention_NN of_IN a_DT timeline_NN or_CC milestones_NNS ._. The_DT
        remit_NN of_IN the_DT plan_NN 's_POS authors_NNS was_VBD not_RB to_TO prescribe_VB specific_JJ research_NN but_CC “ to_TO stimulate_VB both_DT
        researchers_NNS and_CC funders_NNS to_TO explore_VB new_JJ ,_, more_RBR collaborative_JJ ,_, cooperative_JJ ,_, and_CC transparent_JJ
        approaches_NNS …_NN in_IN addition_NN to_TO continuing_VBG the_DT productive_JJ ,_, high-quality_JJ approaches_NNS already_RB
        underway_NN ._.” However_RB ,_, without_IN a_DT timeline_NN ,_, the_DT plan_NN fails_VBZ to_TO convey_VB a_DT sense_NN of_IN urgency_NN ._. This_DT
        is_VBZ problematic_JJ ,_, as_IN any_DT delays_NNS in_IN developing_VBG a_DT vaccine_NN will_MD increase_VB the_DT burden_NN from_IN
        HIV_NNP /_NN AIDS_NNP in_IN the_DT parts_NNS of_IN the_DT world_NN that_WDT can_MD least_JJS afford_VB it_PRP ._. To_TO accelerate_VB vaccine_NN
        development_NN ,_, the_DT plan_NN urgently_RB needs_VBZ to_TO be_VB supplemented_JJ with_IN a_DT list_NN of_IN specific_JJ tasks_NNS ,_,
        responsible_JJ individuals_NNS ,_, necessary_JJ resources_NNS ,_, and_CC allocated_VBD time_NN ._.
        The_DT next_JJ document_NN from_IN the_DT Enterprise_NNP must_MD provide_VB specifics_NNS on_IN project_NN management_NN ,_,
        although_IN one_CD problem_NN with_IN putting_VBG a_DT time_NN frame_NN on_IN HIV_NNP vaccine_NN development_NN is_VBZ a_DT fundamental_JJ
        one_CD :_: we_PRP do_VBP not_RB know_VB whether_IN it_PRP is_VBZ actually_RB possible_JJ to_TO develop_VB a_DT safe_JJ and_CC effective_JJ
        vaccine_NN ._. (_( One_CD assumes_VBZ the_DT Enterprise_NNP members_NNS agree_VBP ,_, though_IN there_EX is_VBZ no_DT explicit_JJ
        acknowledgement_NN of_IN this_DT uncertainty_NN in_IN the_DT plan_NN ._. )_) Moreover_RB ,_, provided_VBN it_PRP can_MD be_VB done_VBN ,_, it_PRP is_VBZ
        impossible_JJ to_TO predict_VB when_WRB the_DT necessary_JJ scientific_JJ advances_NNS will_MD happen_VB ._. That_DT said_VBD ,_,
        without_IN a_DT list_NN of_IN specific_JJ projects_NNS ,_, project_NN leaders_NNS ,_, and_CC a_DT time_NN frame_NN for_IN achieving_VBG or_CC at_IN
        least_JJS evaluating_VBG specific_JJ goals_NNS ,_, it_PRP will_MD be_VB impossible_JJ to_TO define_VB success_NN and_CC failure_NN ,_,
        review_NN progress_NN ,_, and_CC assure_VB internal_JJ and_CC external_JJ accountability_NN ._.
        There_EX is_VBZ another_DT reason_NN why_WRB a_DT best-guess_JJ timeline_NN is_VBZ essential_JJ :_: realistic_JJ expectations_NNS
        about_IN an_DT AIDS_NNP vaccine_NN would_MD stress_VB the_DT urgency_NN of_IN combating_VBG the_DT AIDS_NNP pandemic_JJ over_IN the_DT next_JJ
        decade—and_NN maybe_RB longer—in_NN the_DT absence_NN of_IN an_DT effective_JJ vaccine_NN ._. The_DT potential_JJ benefits_NNS of_IN a_DT
        vaccine_NN cannot_NN be_VB overestimated_JJ ,_, and_CC its_PRP$ development_NN has_VBZ to_TO be_VB one_CD top_JJ priority_NN for_IN the_DT
        global_JJ scientific_JJ community_NN ._. But_CC its_PRP$ success_NN cannot_NN be_VB taken_VBN for_IN granted_VBN and_CC will_MD come_VB too_RB
        late_RB for_IN millions_NNS ._. Therefore_RB ,_, parallel_JJ efforts_NNS to_TO prevent_VB or_CC reduce_VB transmission_NN and_CC to_TO
        treat_VB infected_JJ individuals_NNS need_VBP to_TO be_VB accelerated_VBN now_RB ._.
        The_DT Enterprise_NNP 's_POS plan_NN should_MD be_VB hailed_VBN as_IN a_DT crucially_RB important_JJ outline_NN for_IN vaccine_NN
        development_NN ,_, but_CC the_DT goodwill_NN surrounding_VBG it_PRP wo_MD n't_RB last_VB unless_IN it_PRP is_VBZ quickly_RB followed_VBN up_RP
        with_IN a_DT set_NN of_IN milestones_NNS ,_, and_CC a_DT transparent_JJ process_NN by_IN which_WDT progress_NN will_MD be_VB measured_VBN and_CC
        course_NN corrections_NNS implemented_VBN ._.
      
    
  
